Payment overview · 2025
General Payments
$1,235.12
63 reported records · 15 companies
Healthcare provider profile · identity verified
Daniel Hector Rodriguez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TRINITY, FL · NPI 1356331995
Verified facts
What the public records show
CMS Open Payments records show Daniel Hector Rodriguez, M.D. received $1,235.12 in general payments during 2025 across 63 reported records.
Novo Nordisk Inc accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.88 | 16.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.56 | 13.0% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $136.97 | 11.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.19 | 9.9% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.93 | 8.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.75 | 8.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.70 | 7.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.56 | 5.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.31 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.78 | 4.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.77 | 3.8% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.84 | 2.6% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $31.16 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.64 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.08 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,235.12 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $143.82 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.76 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $122.19 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $122.19 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.25 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $107.12 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.93 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.22 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.70 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.56 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.35 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.66 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.78 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.77 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 98 |
| Lisinopril | Lisinopril | 297 | 98 |
| Alprazolam | Alprazolam | 287 | 62 |
| Metformin Hcl | Metformin Hcl | 230 | 69 |
| Losartan Potassium | Losartan Potassium | 190 | 64 |
| Gabapentin | Gabapentin | 182 | 49 |
| Omeprazole | Omeprazole | 182 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 55 |
| Trazodone Hcl | Trazodone Hcl | 149 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 34 |
| Ozempic | Semaglutide | 127 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 35 |
| Simvastatin | Simvastatin | 111 | 39 |
| Ezetimibe | Ezetimibe | 109 | 35 |
| Eliquis | Apixaban | 107 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 21 |
| Montelukast Sodium | Montelukast Sodium | 97 | 17 |
| Sertraline Hcl | Sertraline Hcl | 86 | 23 |
| Potassium Chloride | Potassium Chloride | 85 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 19 |
| Furosemide | Furosemide | 82 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 11 |
| Carvedilol | Carvedilol | 80 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 17 |
| Januvia | Sitagliptin Phosphate | 69 | 14 |
| Diazepam | Diazepam | 65 | suppressed |
| Pregabalin | Pregabalin | 65 | suppressed |
| Atenolol | Atenolol | 63 | 20 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Tramadol Hcl | Tramadol Hcl | 61 | 20 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Jardiance | Empagliflozin | 57 | 17 |
| Nifedipine Er | Nifedipine | 57 | suppressed |
| Fenofibrate | Fenofibrate | 56 | 13 |
| Lorazepam | Lorazepam | 53 | 11 |
| Famotidine | Famotidine | 51 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Azithromycin | Azithromycin | 48 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 15 |
| Meclizine Hcl | Meclizine Hcl | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 13 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 12 |
| Finasteride | Finasteride | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 16 |
| Allopurinol | Allopurinol | 41 | 11 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 15 |
| Methylprednisolone | Methylprednisolone | 40 | 36 |
| Primidone | Primidone | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Glipizide | Glipizide | 32 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,235.12 · 63 records | Novo Nordisk Inc | ABRYSVO, Arikayce, Brinsupri, CARDIOMEMS, COMIRNATY, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error